Psma targeted fluorescent agents for image guided surgery
US-2017283384-A1 · Oct 5, 2017 · US
US10405753B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10405753-B2 |
| Application number | US-201514937641-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 10, 2015 |
| Priority date | Nov 10, 2015 |
| Publication date | Sep 10, 2019 |
| Grant date | Sep 10, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Sterile and non-toxic pharmaceutical compositions of near IR, closed chain, sulfo-cyanine dyes and methods for visualizing tissue under illumination with near-infrared radiation are provided.
Opening claim text (preview).
What is claimed is: 1. A method of visualizing tissue in a patient, the method comprising the step of administering a sterile pharmaceutical composition comprising a unit dosage form of a compound having the formula: wherein, R 1 , R 2 , R 3 , and R 4 are each independently hydrogen, C 1-3 alkyl, or —CO 2 T; X is a single bond, —O—, or —S—; subscripts a, b, c, and d are each independently an integer from 1 to 6, and T is a metal ion, H, or a negative charge; wherein the composition is non-toxic, and wherein the unit dosage form delivers to the patient an amount sufficient to visualize tissue; and further comprising imaging the tissue under illumination with near-infrared radiation, and obtaining at least one image of the tissue from the patient using the composition. 2. The method of claim 1 wherein the unit dosage form delivers to the patient an amount between 0.05 and 8 mg/kg. 3. The method of claim 1 further comprising obtaining the image during administration, after administration, or both during and after administration of the composition. 4. The method of claim 1 where the step of administering a sterile pharmaceutical composition is by intravenous injection. 5. The method of claim 1 where the composition is injected into a circulatory system. 6. The method of claim 1 further comprising visualizing a patient area on which surgery is or will be performed, or for viewing a patient area otherwise being examined by a medical professional. 7. The method of claim 6 further comprising performing a surgical procedure on the patient area based on the visualization of the surgical area. 8. The method of claim 6 further comprising viewing a patient area on which an ophthalmic, arthroscopic, laparoscopic, cardiothoracic, muscular, or neuro procedure is or will be performed. 9. The method of claim 1 further comprising obtaining ex vivo images of at least a portion of the patient. 10. The method of claim 1 wherein the compound has the formula: wherein, R 1 , R 2 , R 3 , and R 4 are each independently hydrogen, —CH 3 , or —CO 2 T. 11. The method of claim 1 wherein the compound is:
Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title
the substituent being bound through an oxygen atom · CPC title
the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid) · CPC title
adapted for particular medical purposes · CPC title
more than five >CH- groups · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.